Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)

Next Previous
Trial Profile

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu-177 octreotide (Primary) ; Everolimus
  • Indications Gastro-enteropancreatic neuroendocrine tumour
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPETE
  • Sponsors ITM Solucin

Most Recent Events

  • 13 Jun 2025 Status changed from active, no longer recruiting to completed according to an ITM Group media release.
  • 13 Jun 2025 According to a ITM Group media release, data from this trial will be presented in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging(SNMMI) annual meeting, held from June 21 - June 24, 2025 in New Orleans, Louisiana.
  • 30 May 2025 Planned End Date changed from 1 Jun 2029 to 1 Nov 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top